Cancer, Breast Clinical Trial
— MRTOXOfficial title:
Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging
Verified date | July 2017 |
Source | Centre Francois Baclesse |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of this study is to compare the proportions of late enhancement in patients with Left ventricular (LV) dysfunction as Herceptin ® and in a control group consisting of patients who did not have LV dysfunction after 6 months under the same treatment.
Status | Terminated |
Enrollment | 19 |
Est. completion date | May 2017 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Women over 18 years - Free and informed consent signed - Histologically confirmed adenocarcinoma of the breast, metastatic or non-metastatic - LVEF> 50% angioscintigraphy before the start of treatment with Herceptin ®, - Overexpression of HER2 in the invasive component of the primary tumor (3 + 2 + according to ICH or with confirmation of positivity by FISH or CISH) - Patient receiving treatment with Herceptin ®, - Inclusion in the control group: patients treated with Herceptin ® episode without LV dysfunction, - For the inclusion in the Group LV dysfunction: the appearance of a decrease in LVEF during treatment with Herceptin ®, angioscintigraphy identified. Exclusion Criteria: - Heart disease or serious medical conditions do not allow to administer Herceptin ® (documented history of heart failure, angina requiring treatment, severe dyspnoea at rest or oxygen dependency), - History of ischemic heart disease or myocarditis - Known allergy to trastuzumab, murine proteins or any of the excipients - Patients with an indication against the MRI (claustrophobia, ferromagnetic foreign body, pacemaker or implantable defibrillator, known allergy to gadolinium salts) - Renal impairment (creatinine clearance <60 ml / min according to the MDRD formula) - Arrhythmia atrial fibrillation, - Contraindications to the administration of Dotarem ®, - Patient unable to give informed consent, - Adult Trust, - Pregnant or lactating - Patient unable to undergo a medical for geographical, social or psychological. |
Country | Name | City | State |
---|---|---|---|
France | Centre François Baclesse | Caen | |
France | Centre Georges-François Leclerc | Dijon | |
France | Clinique du Bois | Lille | |
France | CHU de NANCY | Nancy |
Lead Sponsor | Collaborator |
---|---|
Centre Francois Baclesse |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportions of late enhancement in patients with LV dysfunction as Herceptin ® and in a control group consisting of patients who did not have LV dysfunction after 6 months under the same treatment. | A cardiac MRI is considered positive if demonstrated a late hyperintense from 15 to 20 minutes after injection of gadolinium chelate, whatever its size, topography subepicardial (intramyocardial) and without vascular systematization. The primary endpoint is the proportion of delayed enhancement in the LV dysfunction group and the control group. |
2 years | |
Secondary | Proportion of patients recovering at 6 months in the absence of late enhancement signal in MRI heart after injection of gadolinium and compare the results of biological assays | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04416087 -
Exercise and Tumor Blood Flow in Breast Cancer Patients
|
N/A | |
Active, not recruiting |
NCT04726319 -
Family History App in Personalized Medicine
|
N/A | |
Recruiting |
NCT05800834 -
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
|
Phase 2 | |
Completed |
NCT04692168 -
Influence of Chemotherapy on Postural Control in Women With Cancer
|
||
Recruiting |
NCT06152419 -
Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project
|
N/A | |
Recruiting |
NCT03709134 -
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
|
||
Completed |
NCT03282214 -
A Self-Management Energy Conservation Program for Cancer-Related Fatigue
|
Phase 2 | |
Recruiting |
NCT06275321 -
Physical Exercise Benefits for Cancer Patients
|
N/A | |
Recruiting |
NCT05711030 -
Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery
|
N/A | |
Suspended |
NCT03271853 -
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
|
N/A | |
Active, not recruiting |
NCT03144947 -
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients
|
Phase 2 | |
Completed |
NCT02996201 -
Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT05573022 -
Impact of a Patient Decision Aid Intervention
|
N/A | |
Completed |
NCT05161312 -
A Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients - a Randomised Clinical Trial
|
N/A | |
Completed |
NCT04836221 -
Comorbidities And Reducing inEquitieS
|
N/A | |
Recruiting |
NCT06345534 -
FAST-FORWARD vs HAI5
|
N/A | |
Recruiting |
NCT06391749 -
Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
|
||
Enrolling by invitation |
NCT06409221 -
VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study
|
||
Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
Completed |
NCT03612934 -
The Impact of SPC on Advanced Breast Cancer Patients
|